Evogene Ltd. · NASDAQ:EVGN
Evogene — Investor Presentation (January 2024)
44 slides from Evogene's investor presentation, Jan 9, 2024
Slide 1: Company Presentation
COMPANY PRESENTATION Ofer Haviv, President & CEO January 9, 2024
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of simi
Slide 3: Agenda
Agenda About Evogene Business Model Success Stories Summary Annex I - Financial overview Annex II - Evogene subsidiaries 3
Slide 4: Our Vision: Decoding Biology
OUR VISION DECODING BIOLOGY Revolutionize the development of life-science based products, utilizing cutting edge computational biology technologies 4
Slide 5: Life Science Product Development – Current State
Life Science Product Development – Current State Pharma Ag-chemicals Industry Industry Cost of developing a single Years to develop a new crop pharmaceutical drug protection product In the 1970’s 1995: 8Y $180 million 2000: 9Y 2005-2018: 10Y In recent years >$2 billion 2010-2015: 11+Y Low probabilit
Slide 6: The Ultimate Case of Finding the Needle in the Haystack
The Ultimate Case of Finding the “Needle in the Haystack” The challenge: finding the winning candidates out of a vast number of possible prospects that address a complex myriad of criteria, to reach successful products Discovery Optimization Development Regulation Approved Product AGRICULTURE PHARMA
Slide 7: The Opportunity
The Opportunity Utilizing advanced computational biology technologies AGRICULTURE to discover and optimize the most & FOOD promising candidates addressing multiple development challenges towards successful life-science based products Increase Reduce Reduce probability time cost of success PHARMA & O
Slide 8: Our Solution
Our Solution When Biology Meets Disruptive Technologies platform BIOLOGY Incorporating deep scientific BIG DATA AI understanding with big data and advanced AI technologies, to successfully discover & guide the optimization of novel life-science based products – Computational Predictive Biology 8
Slide 9: Tailored AI Tech-Engines
Tailored AI Tech-Engines MICROBES The CPB platform directs and accelerates product discovery and optimization through dedicated AI Tech-Engines for products SMALL based on three core components: MOLECULES ▪ Microbes ▪ Small molecules ▪ Genetic elements GENETIC ELEMENTS 9
Slide 10: AI Tech-Engines to direct & accelerate product discovery & optimization
AI Tech-Engines Discovery Optimization to direct & accelerate Computational selection of the most promising Computational driven solution addressing optimization challenges product discovery & candidates to initiate the for the selected candidates, product development without impairing their ability
Slide 11: AI Tech-Engine Dashboard (Example)
AI Tech-Engine Dashboard (Example) 11
Slide 12: Potential Markets for MicroBoost AI
Potential Potential Markets for MicroBoost AI (Example) Market Diversity Microbials for Crops Therapeutic microbials Food Probiotics OD PHA Structuring an FO RM & A ’ecosystem’ of diverse RE Dietary & Human & AGRI ULTU Animal Probiotics Supplements WE product types to be LLNESS developed utilizing o
Slide 13: Agenda
Agenda About Evogene Business Model Success Stories Summary Annex I – Financial overview Annex II – Evogene subsidiaries 13
Slide 14: Evogene's AI Tech-Engines - Potential Markets
Evogene’s AI Tech-Engines - Potential Markets MICROBES SMALL MOLECULES GENETIC ELEMENTS Microbials Crop Improved Medical Therapeutic for crops protection Pharmaceuticals crops Cannabis microbials Gene Chemical therapy Food stimulants Alternative Advanced Probiotics food wound care OD PHA OD FO RM OD
Slide 15: Business Strategy
Business Strategy Capture the value of our AI tech-engines as product-development enablers, through two types of business models: Licensing A time-limited license grant to utilize one of Evogene’s tech-engines, to a third party for product development in a defined commercial field. In most cased the
Slide 16: Licensing
1 | Business Model Licensing Evogene’s AI Tech-Engines to a third party (currently, all Evogene subsidiaries) Licensing Potential revenue stream • License fees & R&D reimbursement • Dividends to Evogene as a shareholder • Significant one-time-payment upon an exit event* Powered by: *As long as Evoge
Slide 17: Collaboration
2 | Business Model Collaborations Driven by Evogene’s AI Tech-Engines with Collaboration Leading Life-Science Companies Potential revenue stream • Upfront payments • R&D fees • Milestone payments • Royalties from sale of end-products Powered by: 17
Slide 18: Licensing & Collaboration - Current Status
Licensing & Collaboration - Current Status Licensing / Subsidiaries Collaboration MICROBES SMALL MOLECULES GENETIC ELEMENTS Microbials for crops Therapeutic microbials Crop protection Pharmaceuticals Improved crops Medical Cannabis OD PHA OD OD FO RM FO FO & & P & P A RE RE E H HA & AGRI ULTUR AR AG
Slide 19: Agenda
Agenda About Evogene Business Model Success Stories Summary Annex I – Financial overview Annex II – Evogene subsidiaries 19
Slide 20: Lavie Bio Mission
Evogene’s Mission Improve food quality, sustainability and agricultural productivity Subsidiary through microbiome-based, ag-biological products Ag-biologicals Unique AI Broad & Strategic 2 revenue- a rapidly growing tech-platform diverse partners & generating market and data assets pipeline investo
Slide 21: Yalos – Bio-inoculant for cereal grains
Powered by Evogene’s Subsidiary Yalos™ - Bio-inoculant for cereal grains* Sold in USA** Superior performance Consistent performance & expanding globally vs. alternatives providing farmers 4:1 ROI 6% Check Yield improvement (%) 5% 4% 3% 2% 1% Other Ag-biologicals Control * Yalos™ has regulatory appro
Slide 22: MicroBoost AI tech-engine directing product discovery & optimization
MicroBoost AI tech-engine Powered by Evogene’s directing & accelerating product Subsidiary discovery & optimization Computational analysis of DB Powered by Experimental validation - Commercial viability and optimization ~100,000 5% success - Bacterial computational Bacterial teaming by function stra
Slide 23: LAV311 - Bio-pesticide for Fruit rots & Powdery mildew
Powered by Evogene’s LAV311 - Bio-pesticide for Fruit rots & Subsidiary Powdery mildew Licensing agreement with Superior performance Consistent performance compared to competing biological control in preventative application over 3 years products, similar results to chemicals (validated by Corteva)
Slide 24: MicroBoost AI tech-engine directing product discovery & optimization
MicroBoost AI tech-engine Powered by Evogene’s directing & accelerating product Subsidiary discovery & optimization Computational machine learning Powered by Experimental ~100,000 validation Commercial viability and Bacterial 15% success optimization strains 400 Powered by Bacterial strains 60 Bacte
Slide 25: Casterra Mission
Evogene’s Mission Subsidiary Provide elite castor seeds to the bio-based industries Unique tech 3 Commercial Castor oil - Holistic Strategic platform for elite revenue generating emerging market ag-solution alliance varieties castor varieties The global castor oil & Combining deep scientific Proprie
Slide 26: EVF716, EVF712, EVF701 Elite Castor Varieties
Powered by Evogene’s EVF716, EVF712, EVF701 Subsidiary Elite Castor Varieties * Variety performance is subjected to weather conditions and to precipitation 26
Slide 27: Castor Seed Sales
Powered by Evogene’s Subsidiary Castor Seed Sales $9.1 Million $2.2 Million * Variety performance is subjected to weather conditions and to precipitation 27
Slide 28: GeneRator AI tech engine directing product discovery & optimization
GeneRator AI tech engine Powered by Evogene’s Subsidiary directing & accelerating product discovery & optimization Breeding programs of varieties suitable for mechanized harvest High-throughput Powered by genetic screening for Genetic high yield & oil traits diversity Powered by ~200 * WW germplasm
Slide 29: Agenda
Agenda About Evogene Business Model Success Stories Summary Annex I – Financial overview Annex II – Evogene subsidiaries 29
Slide 30: The Evogene Group
The Evogene 142 Employees Group 29 % PhDs 50% Women (76%*) (70%*) (98%*) (100%*) (100%*) As of Nov 13, 2023 *Evogene holdings 30
Slide 31: Our Vision
Our vision Our unique offering - 3 AI Tech-Engines to direct & accelerate product discovery and optimization: Current subsidiaries • Biomica – Human-microbiome based therapeutics Revolutionize the • MicroBoost AI • Lavie Bio – Ag-biologicals development of life-science • ChemPass AI • AgPlenus – Ag-
Slide 32: Thank You!
THANK YOU!
Slide 33: Annex I: Financial Overview
Annex I: Financial Overview 33
Slide 34: Key Financials: Balance Sheet
Key Financials: Thousands of US $ 30.09.2023 31.12.2022 Balance Sheet Current Assets 40,555 37,751 Long-Term Assets 17,191 18,375 Key Points: • Consolidated cash position: ~$37 million as of 30.09.2023 Total Assets 57,746 56,126 • This Consolidated cash position does not include the $2.5 million, wh
Slide 35: Annex II: Evogene Subsidiaries
Annex II: Evogene Subsidiaries 35
Slide 36: Evogene Subsidiaries
Evogene Subsidiaries 76%* 70%* 98%* 100%* 100%* Microbiome-based Ag Biologicals Ag Chemicals Medical Cannabis Castor Cultivation Therapeutics End-to-End Solution • Immuno-oncology • Bio-stimulants • Herbicides • High yield & consumer • Elite castor varieties traits • Cultivation protocols • GI- rela
Slide 37: Biomica: Mission, Products & Pipeline
| Human Microbiome Powered by Mission: Discovery and development of novel therapies for microbiome-related human disorders using computational biology Products & Pipeline Expected upcoming value drivers Immuno-oncology program Immuno-oncology ▪ Readout & completion of POC from first in-human study;
Slide 38: Example Results: Immuno-Oncology program – BMC128
| Human Microbiome Powered by Example Results: Immuno-Oncology program – BMC128 potentiate the effect of anti-PD-1 therapy (immunotherapy) in-vivo Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone 38
Slide 39: Lavie Bio: Mission, Products & Pipeline
| Ag-Biologicals Powered by Mission: Improve food quality, sustainability & agriculture productivity through microbiome based ag-biologicals technology & products Products & Pipeline (examples) Expected upcoming value drivers Bio-stimulants Bio-stimulants ▪ Yalos™ – primarily spring wheat: commercia
Slide 40: Example Results: Ag-Biologicals
Powered by | Ag-Biologicals Example Results: - Yalos™ inoculant for spring wheat - LAV 311 bio-fungicide candidates for fruit rot Lavie Bio’s wheat field in the USA during harvest – Sales initiated in 2022 Example of treatment against Botrytis Cinerea vs untreated • License for LAV 311 & LAV 312 bio
Slide 41: AgPlenus: Products & Pipeline
| Ag-Chemicals Powered by Mission: Design next-generation, effective, and sustainable crop protection products by leveraging predictive chemistry and biology Products & Pipeline Expected upcoming value drivers Herbicides Herbicides ▪ Novel Mode-of-Action selective herbicide ▪ Milestone achievement o
Slide 42: Example Results: Ag-Chemicals
| Ag-Chemicals Powered by Example Results: New MoA Herbicide – APH1 (weed) Field test of APH1 against a panel of grass and broadleaf weeds – untreated control vs APH1 Greenhouse testing of APH1 – Conferring resistance by modifying tobacco 42
Slide 43: Casterra: Product & Pipeline
| Biobased Materials Powered by Mission: Leading the castor oil market with an integrated solution for industrialized cultivation of castor in support of the biobased materials industry Product & Pipeline Expected upcoming value drivers Elite castor seed varieties Seeds development ▪ ‘EVF’ series -
Slide 44: High Yield & Oil Castor Seeds
Powered by | Biobased Materials High Yield & Oil Castor Seeds Elite castor seed varieties – The ‘EVF’ series EVF701 EVF712 EVF716 Dedicated machinery Castor growth protocol Mechanical Harvest Proprietary dehulling machine 44